Shining a light on intestinal traffic

Loading...
Thumbnail Image
Files
Published_Review_article.pdf(1.07 MB)
Published Version
Date
2012-01
Authors
Murphy, Carola T.
Nally, Kenneth
Shanahan, Fergus
Melgar, Silvia
Journal Title
Journal ISSN
Volume Title
Publisher
Hindawi Publishing Corporation
Published Version
Research Projects
Organizational Units
Journal Issue
Abstract
Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is associated with enhanced leukocyte infiltration to the gut, which is directly linked to the clinical aspects of these disorders. Thus, leukocyte trafficking is a major target for IBD therapy. Past and emerging techniques to study leukocyte trafficking both in vitro and in vivo have expanded our knowledge of the leukocyte migration process and the role of inhibitors. Various strategies have been employed to target chemokine- and integrin-ligand interactions within the multistep adhesion cascade and the S1P/S1PR1 axis in leukocyte migration. Though there is an abundance of preclinical data demonstrating efficacy of leukocyte trafficking inhibitors, many have yet to be confirmed in clinical studies. Vigilance for toxicity and further research is required into this complex and emerging area of IBD therapy.
Description
Keywords
IBD , Leukocyte infiltration , Leukocyte trafficking inhibitors
Citation
Carola T. Murphy, Kenneth Nally, Fergus Shanahan, and Silvia Melgar, “Shining a Light on Intestinal Traffic,” Clinical and Developmental Immunology, vol. 2012, Article ID 808157, 14 pages, 2012. doi:10.1155/2012/808157